August 30, 2025 a 09:01 am
MDT: Analysts Ratings - Medtronic plc
Medtronic plc, a leader in the medical device sector, continues to draw varied analyst opinions. While some analysts maintain a bullish stance, there’s a noticeable shift towards more cautious recommendations. Although the company demonstrates resilience in the healthcare market, the mixed analyst ratings suggest potential uncertainties amidst ongoing market dynamics.
Historical Stock Grades
| Recommendation | Number | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 13 | |
| Hold | 15 | |
| Sell | 1 | |
| Strong Sell | 1 |
Sentiment Development
Over recent months, there is a notable increase in Hold recommendations while Strong Buy ratings have declined. This suggests a cautious outlook among analysts, reflecting possible concerns. - Total ratings have shown fluctuations, with a slight decline in Buy ratings from earlier months. - A consistent increase in the number of Hold recommendations highlights a trend towards uncertainty. - The number of Sell and Strong Sell ratings remains low, indicating limited negativity in the analyst sentiment.
Percentage Trends
There is a nuanced shift in analyst opinions with a moderate decrease in Strong Buy and a rise in Hold ratings over the last year. - Percentage of Strong Buy ratings dropped from 26% in early 2024 to 13% in August 2025. - Hold ratings percentage increased significantly, reflecting a more balanced stance toward the stock. - The trend suggests a growing caution amongst analysts, potentially due to external economic factors impacting Medtronic's market environment.
Latest Analyst Recommendations
Recent analyst recommendations for Medtronic plc display a trend towards maintaining existing ratings, indicating a stable outlook for the company.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-26 | Buy | Buy | Argus Research |
| 2025-08-21 | Buy | Buy | Citigroup |
| 2025-08-21 | Hold | Hold | Truist Securities |
| 2025-08-20 | Outperform | Outperform | Bernstein |
| 2025-08-20 | Overweight | Overweight | Wells Fargo |
Analyst Recommendations with Change of Opinion
The following table highlights recent changes in analyst opinions, indicating adjustments in outlook.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-06-30 | Peer Perform | Underperform | Wolfe Research |
| 2025-03-04 | Buy | Neutral | Citigroup |
| 2024-10-10 | Outperform | Sector Perform | RBC Capital |
| 2024-08-15 | Neutral | Sell | UBS |
| 2024-08-14 | Hold | Buy | Stifel |
Interpretation
The current analyst sentiment towards Medtronic reflects a balanced stance with a lean towards caution. The persistence of Hold ratings suggests a level of uncertainty in the market, possibly reflecting external pressures or anticipated challenges. The few shifts in recommendation indicate a broad alignment among analysts that market conditions or company performance may not warrant aggressive buy signals. Overall, this suggests a degree of confidence, albeit with prudent consideration of market variables.
Conclusion
Medtronic plc remains a stable entity within the medical device market despite mixed analyst ratings. The shift towards Hold recommendations underscores a growing prudence among analysts, reflective of an evolving economic landscape. While immediate risks may be limited, attention to external market conditions and company performance indicators will be essential for future assessments. This balance of caution and stability in analyst opinion suggests a steady but vigilant approach is advisable for stakeholders.